Eloralintide: the amylin agonist's phase 2 data and phase 3 trials
Prepared by: Research Desk. Sources are linked for verification.
Published 27 October 2026
At a glance
- What it is: eloralintide is an investigational peptide developed by Eli Lilly, described by its developers as a selective amylin receptor agonist
- Peer-reviewed data: a 48-week, placebo-controlled phase 2 trial in 263 adults with obesity or overweight, published in The Lancet in November 2025
- Newer, not yet peer-reviewed: on 30 September 2026 Lilly reported phase 2b results for eloralintide combined with tirzepatide in adults with type 2 diabetes
- Phase 3: the ENLIGHTEN trials of eloralintide alone are recruiting, and two AMPLIFY trials of a combination are registered but not yet recruiting
- Status: eloralintide is not approved anywhere; every result below comes from clinical trials
Why amylin
Amylin is a 37-amino-acid peptide hormone released from pancreatic beta cells together with insulin. A review in Pharmacological Reviews (Hay et al., 2015) describes its receptors as complexes of the calcitonin receptor with receptor activity-modifying proteins (RAMPs), and summarises animal and human work linking amylin signalling to slower gastric emptying, lower glucagon release after meals and reduced food intake.
Native human amylin aggregates readily, which is one reason drug programmes have built modified analogues. Cagrilintide, the amylin component of Novo Nordisk's CagriSema, is one; eloralintide is Lilly's.
The phase 2 trial in The Lancet
Billings et al. (2025), published online on 6 November 2025, reported a double-blind trial (NCT06230523) at 46 centres in the United States.
- Participants: 263 adults with a body-mass index of at least 30, or at least 27 with a weight-related condition, and without type 2 diabetes; mean age 49 years, mean body-mass index 39.1, and 78% female; the trial ran from February 2024 to August 2025
- Design: participants were randomly assigned to placebo or to one of six eloralintide arms (four fixed strengths and two stepwise schemes), given by injection every week for 48 weeks
- Weight change: mean change at week 48 ranged from about −9% to −20% across the eloralintide arms, versus −0.4% with placebo (efficacy estimand)
- Adverse events: nausea was reported in 11% to 64% of participants across the eloralintide arms and 14% with placebo, and fatigue in up to 46% versus 12% with placebo
- Funding: Eli Lilly, with company employees among the authors
The efficacy estimand assumes participants stayed on the assigned regimen. Figures based on all randomised participants are typically smaller, so the two should not be mixed when comparing trials.
Phase 2b: eloralintide with tirzepatide
On 30 September 2026, Lilly announced in a press release phase 2b results for the combination it calls EloraTZP (NCT06603571), presented at the European Association for the Study of Diabetes meeting in Milan.
- Participants: 367 adults with obesity or overweight and type 2 diabetes, in the United States and Argentina
- Weight change: up to −23.3% with the combination, versus −14.8% with tirzepatide alone, up to −12.3% with eloralintide alone and −3.0% with placebo (efficacy estimand)
- Glycated haemoglobin: reductions of up to 2.9 percentage points with the combination, versus 2.4 with tirzepatide alone
- Stopping because of adverse events: 10.8% to 27.0% of participants in the combination arms, 0% to 10.8% with eloralintide alone, 2.9% with tirzepatide alone and 16.7% with placebo
- Next step: Lilly said it plans to start phase 3 trials of a co-formulated product by the end of 2026
These figures come from a company announcement and a meeting presentation. They have not yet appeared in a peer-reviewed paper, so the full methods, subgroup data and safety tables cannot be checked.
The phase 3 programme on ClinicalTrials.gov
The registry lists the following eloralintide trials (records checked 27 October 2026):
- ENLIGHTEN-1 (NCT07321886): obesity or overweight, about 1,980 participants, recruiting since February 2026
- ENLIGHTEN-2 (NCT07282600): obesity or overweight with type 2 diabetes, about 1,035 participants, recruiting since December 2025
- ENLIGHTEN-3 (NCT07369011): obesity with obstructive sleep apnoea, about 800 participants
- ENLIGHTEN-4 (NCT07353931): obesity with knee osteoarthritis pain, about 900 participants
- ENLIGHTEN-6 (NCT07392190): people with persistent obesity while already on a weekly incretin medicine, about 900 participants
- AMPLIFY-1 (NCT07881432) and AMPLIFY-2 (NCT07881458): the eloralintide–tirzepatide combination, without and with type 2 diabetes, registered with planned starts in late 2026 and not yet recruiting
Estimated primary completion dates run from early 2028 for the ENLIGHTEN trials to late 2029 for AMPLIFY. No phase 3 results have been reported.
Limitations of the evidence
- One peer-reviewed trial: the only published efficacy data come from a single phase 2 trial of 263 people, run in one country
- Sponsor involvement: the trials are funded by Eli Lilly, and company employees are among the authors
- Press-release data: the combination results are not yet peer-reviewed
- Surrogate measures: body weight and glycated haemoglobin are not outcome measures such as heart attacks or deaths
- Tolerability: nausea and fatigue were common in the higher-strength arms, and discontinuation rates in the phase 2b combination arms were substantial
Key terms
- Amylin receptor: a calcitonin receptor paired with a receptor activity-modifying protein (RAMP), which changes which hormones it responds to
- Estimand: a precise definition of what a trial result measures, including how events such as stopping the study drug are handled
- Phase 2b: a larger mid-stage trial used to choose strengths and confirm signals before phase 3
- Co-formulation: two active ingredients combined in a single product
Supplier
Purita is a store that sells peptides for laboratory research use only. It does not list eloralintide, which is an investigational pharmaceutical product; the link below goes to the store's homepage.
Affiliate disclosure: this is a paid link. KlowSignal earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the affiliate disclosure.
Related pages
- Research peptide signals: studies and regulatory updates
- About KlowSignal
- How to read a research or regulatory signal
- Survodutide phase 3: what the SYNCHRONIZE trials have reported so far
- CagriSema phase 3: what the REDEFINE trials have reported so far
- Retatrutide phase 3: TRIUMPH-1 and TRIUMPH-2 results published
More from KlowSignal
How to read a research or regulatory signal
What a cell study, a phase 3 trial, a press release or an FDA list entry can and cannot tell you, with key regulatory vocabulary and a checklist for each signal.
FDA compounding committee, July 2026: seven research peptides listed
FDA's Pharmacy Compounding Advisory Committee agenda for 23–24 July 2026 lists BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. Here is what the record says.
Elamipretide (SS-31): the 2025 accelerated approval on the record
SS-31 is a Szeto-Schiller tetrapeptide studied for its binding to cardiolipin. In September 2025 FDA granted accelerated approval to elamipretide for Barth syndrome. Here is what the record shows.
Retatrutide phase 3: TRIUMPH-1 and TRIUMPH-2 results published
On 29 September 2026 the first two TRIUMPH phase 3 trials of retatrutide, a GIP, GLP-1 and glucagon receptor agonist, appeared in NEJM and The Lancet. Here is what the papers report.
WADA Prohibited List: how BPC-157 and TB-500 are classed and detected
How the World Anti-Doping Agency classifies unapproved research peptides under Categories S0 and S2, and how mass spectrometry labs detect BPC-157 and TB-500 metabolites.
Thymosin alpha-1 in sepsis: the TESTS phase 3 trial on the record
The 1,106-participant TESTS trial in The BMJ found no difference in 28-day mortality between thymosin alpha-1 and placebo in adults with sepsis. What the record shows.
CagriSema phase 3: what the REDEFINE trials have reported so far
REDEFINE 1, 2 and 5 have published results for CagriSema, the investigational cagrilintide and semaglutide combination. What each paper and the REDEFINE 3 design report.
Survodutide phase 3: what the SYNCHRONIZE trials have reported
SYNCHRONIZE-1 and SYNCHRONIZE-2 in the NEJM and SYNCHRONIZE-MASLD in Nature Medicine have reported results for survodutide, an investigational glucagon/GLP-1 dual agonist.